Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 5/20 | 0.66 |
| ▸ | RXRA | P19793 | 2/20 | 0.66 |
| ▸ | RXRB | P28702 | 2/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CBS | P35520 | 1/20 | 0.55 |
| ▸ | RPA1 | P27694 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.53 |
| ▸ | AHR | P35869 | 1/20 | 0.52 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | PLAU | P00749 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31312218 | 0.86 | RXRA (0.62) | KMORXRARXRBLMNAGAA | |
| SCHEMBL23296152 | 0.84 | RXRA (0.60) | KMORXRARXRBLMNAGAA | |
| SCHEMBL3208003 | 0.84 | KMO (0.62) | KMORXRARXRBLMNAGAA | |
| SCHEMBL29577419 | 0.84 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL14683877 | 0.84 | KMO (0.87) | KMORXRARXRBLMNAGAA | |
| SCHEMBL29904709 | 0.84 | KMO (0.86) | KMORXRARXRBTSHRLMNA | |
| SCHEMBL30725957 | 0.84 | KMO (0.86) | KMORXRARXRBTSHRLMNA | |
| SCHEMBL71238 | 0.84 | KMO (0.86) | KMORXRARXRBTSHRLMNA | |
| SCHEMBL410752 | 0.84 | RXRA (0.69) | KMORXRARXRBERN1PLAU | |
| SCHEMBL307574 | 0.83 | RXRA (0.73) | KMORXRARXRBTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | Technische Universität Dresden (DE) | 2022-01-04 | — | — | US | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| EP-3819006-A1 | COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-12 | — | — | EP | disclosed |
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | Technische Universität Dresden (DE) | 2021-05-06 | — | — | US | disclosed |
| US-7727990-B2 | Melanocortin receptor-specific piperazine and keto-piperazine compounds | PALATIN TECHNOLOGIES, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1919479-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | Palatin Technologies, Inc. (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007021991-A2 | MELANOCORTIN RECEPTOR-SPECIFIC PIPERAZINE AND KETO-PIPERAZINE COMPOUNDS | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-22 | — | — | WO | disclosed |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210130328-A1 | NOVEL COMPOUNDS WITH THYMINE SKELETON FOR USE IN MEDICINE | TMSB10, TMSB4X, TBCA | KMO 4384/4885RXRA 2787/4885RXRB 2403/4885 |
| US-20060287332-A1 | Melanocortin Receptor-Specific Piperazine and Keto-Piperazine Compounds | MC4R, MC5R, MC1R | KMO 262/4885RXRA 223/4885RXRB 160/4885 |
| US-11214564-B2 | Compounds with thymine skeleton for use in medicine | TMSB10, TMSB4X, TBCA | KMO 4330/4885RXRA 2730/4885RXRB 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.